Pub Date : 2024-06-01Epub Date: 2024-05-07DOI: 10.3341/kjo.2024.0010
Hyunjean Jung, Junwon Lee, Christopher Seungkyu Lee, Min Kim, Sung Soo Kim, Suk Ho Byeon, Jay Jiyong Kwak
Purpose: This study sought to compare the long-term outcomes of surgeries for retinal detachment (RD) secondary to viral or parasitic infectious retinitis.
Methods: A total of 47 eyes that received pars plana vitrectomy with or without scleral buckling due to RD secondary to polymerase chain reaction-proven viral (cytomegalovirus, varicella zoster virus, and herpes zoster virus) or parasitic (toxoplasma and toxocara) retinitis from October 1, 2006, to June 30, 2023, in a single medical center were retrospectively enrolled.
Results: Mean follow-up period was 59.03 ± 55.24 months in viral retinitis and 34.80 ± 33.78 months in parasitic retinitis after primary reattachment surgery. During follow-up, nine eyes (24.3%) with viral retinitis and five eyes (50.0%) with parasitic retinitis developed retinal redetachment. Visual acuity success at final follow-up was achieved in 19 eyes (51.4%) with viral retinitis and six eyes (60.0%) with parasitic retinitis (p = 0.64). The incidence of retinal redetachment during the 1st postoperative year was significantly higher in parasitic retinitis compared with viral retinitis (crude incidence, 0.21 vs. 0.85; p = 0.02). Hazard ratio analysis adjusted for age and sex showed 4.58-fold (95% confidence interval, 1.22-17.27; p = 0.03) increased risk of retinal redetachment in parasitic retinitis compared with viral retinitis during the 1st postoperative year. Tamponade with silicone oil and preoperative diagnostic vitrectomy were associated with significantly decreased risk of retinal redetachment in patients with parasitic retinitis.
Conclusions: Compared with RD secondary to viral retinitis, RD secondary to parasitic retinitis showed higher incidence of retinal redetachment during the 1st postoperative year. Tamponade with silicone oil and preoperative diagnostic vitrectomy were associated with significantly decreased risk of retinal redetachment in patients with parasitic retinitis.
{"title":"Long-term Outcomes of Surgeries for Retinal Detachment Secondary to Parasitic or Viral Infectious Retinitis.","authors":"Hyunjean Jung, Junwon Lee, Christopher Seungkyu Lee, Min Kim, Sung Soo Kim, Suk Ho Byeon, Jay Jiyong Kwak","doi":"10.3341/kjo.2024.0010","DOIUrl":"10.3341/kjo.2024.0010","url":null,"abstract":"<p><strong>Purpose: </strong>This study sought to compare the long-term outcomes of surgeries for retinal detachment (RD) secondary to viral or parasitic infectious retinitis.</p><p><strong>Methods: </strong>A total of 47 eyes that received pars plana vitrectomy with or without scleral buckling due to RD secondary to polymerase chain reaction-proven viral (cytomegalovirus, varicella zoster virus, and herpes zoster virus) or parasitic (toxoplasma and toxocara) retinitis from October 1, 2006, to June 30, 2023, in a single medical center were retrospectively enrolled.</p><p><strong>Results: </strong>Mean follow-up period was 59.03 ± 55.24 months in viral retinitis and 34.80 ± 33.78 months in parasitic retinitis after primary reattachment surgery. During follow-up, nine eyes (24.3%) with viral retinitis and five eyes (50.0%) with parasitic retinitis developed retinal redetachment. Visual acuity success at final follow-up was achieved in 19 eyes (51.4%) with viral retinitis and six eyes (60.0%) with parasitic retinitis (p = 0.64). The incidence of retinal redetachment during the 1st postoperative year was significantly higher in parasitic retinitis compared with viral retinitis (crude incidence, 0.21 vs. 0.85; p = 0.02). Hazard ratio analysis adjusted for age and sex showed 4.58-fold (95% confidence interval, 1.22-17.27; p = 0.03) increased risk of retinal redetachment in parasitic retinitis compared with viral retinitis during the 1st postoperative year. Tamponade with silicone oil and preoperative diagnostic vitrectomy were associated with significantly decreased risk of retinal redetachment in patients with parasitic retinitis.</p><p><strong>Conclusions: </strong>Compared with RD secondary to viral retinitis, RD secondary to parasitic retinitis showed higher incidence of retinal redetachment during the 1st postoperative year. Tamponade with silicone oil and preoperative diagnostic vitrectomy were associated with significantly decreased risk of retinal redetachment in patients with parasitic retinitis.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"236-248"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11175980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-01Epub Date: 2024-05-22DOI: 10.3341/kjo.2024.0031
Jeong Woo Park, Jin Sook Yoon
Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves disease. There has been no effective medication to prevent proptosis in thyroid eye disease until 2020 when the anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody, Teprotumumab, was approved by the US Food and Drug Administration, sparking increased interest in immune-based drug development. This study aims to review the newly developed drug therapy as well as conventional treatment for TED. Treatment of TED has traditionally been high-dose steroids and orbital radiotherapy, but recently there has been a paradigm shift in the treatment of TED in the United States with the introduction of the therapeutic agent teprotumumab, which dramatically reduces proptosis. However, concerns remain about the development of hearing impairment as a potentially fatal complication and long-term safety. Recently, several clinical trials are underway to assess the efficacy and safety of novel drugs targeting mammalian target of rapamycin complex 1, interleukin-6, fragment crystallizable receptor, and IGF-1R in treating TED. With the explosive increase in interest from academia and pharmaceutical companies in TED, there is anticipation for the development of drugs that are equivalent or superior to teprotumumab while being safer.
{"title":"A Review of Novel Medical Treatments for Thyroid Eye Disease.","authors":"Jeong Woo Park, Jin Sook Yoon","doi":"10.3341/kjo.2024.0031","DOIUrl":"10.3341/kjo.2024.0031","url":null,"abstract":"<p><p>Thyroid eye disease (TED) is the most common extrathyroidal manifestation of Graves disease. There has been no effective medication to prevent proptosis in thyroid eye disease until 2020 when the anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody, Teprotumumab, was approved by the US Food and Drug Administration, sparking increased interest in immune-based drug development. This study aims to review the newly developed drug therapy as well as conventional treatment for TED. Treatment of TED has traditionally been high-dose steroids and orbital radiotherapy, but recently there has been a paradigm shift in the treatment of TED in the United States with the introduction of the therapeutic agent teprotumumab, which dramatically reduces proptosis. However, concerns remain about the development of hearing impairment as a potentially fatal complication and long-term safety. Recently, several clinical trials are underway to assess the efficacy and safety of novel drugs targeting mammalian target of rapamycin complex 1, interleukin-6, fragment crystallizable receptor, and IGF-1R in treating TED. With the explosive increase in interest from academia and pharmaceutical companies in TED, there is anticipation for the development of drugs that are equivalent or superior to teprotumumab while being safer.</p>","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":" ","pages":"249-259"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11175988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose To assess efficacy, safety, and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015%/timolol 0.5% (PF tafluprost/timolol FC) in treatments-naïve patients with primary open-angle glaucoma (POAG). Methods This was a retrospective, real-world clinical practice setting study that included 107 eyes of 107 subjects with POAG who had never been treated for glaucoma. All subjects were received PF tafluprost/timolol FC once daily. Intraocular pressure (IOP) levels were documented for each eye at the untreated baseline and up to six months after the initiation of medical treatment. All adverse events, including ocular and systemic adverse reactions, were recorded. Additionally, the reasons for medication discontinuations were thoroughly documented. Results A total of 32 POAG patients with high-baseline IOP (> 21 mmHg) and 75 with normal-baseline IOP were included in the study. The subjects' baseline mean age was 62.4 ± 8.7 (range: 26 - 85 years); among them, 42 were women (39.3%). Mean IOP at baseline for all patients was 18.6 ± 4.3 mmHg. The mean IOP at six months was 12.6 ± 4.7 mmHg, representing a significant decrease compared to the baseline (-32%; P< 0.001). In POAG patients with high-baseline IOP, mean IOP was significantly lowered from 28.0 ± 5.7 mmHg at baseline to 18.0 ± 5.5 mmHg (-35%; P< 0.001); in patients with normal-baseline IOP, from 14.6 ± 3.4 mmHg to 10.3 ± 4.1 mmHg (-29%; P< 0.001). PF tafluprost/timolol FC was well tolerated and safe. After 6 months, 97.2% of all patients remained on therapy. Conclusions In this real-world observational study, once-daily treatment with PF tafluprost/timolol FC demonstrated clinically relevant and statistically significant efficacy, as well as safety and good tolerability, in treatment-naive patients diagnosed with POAG.
{"title":"Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma.","authors":"Teakkwan Rhee, Jaeheon Kim, Ahnul Ha","doi":"10.3341/kjo.2024.0021","DOIUrl":"https://doi.org/10.3341/kjo.2024.0021","url":null,"abstract":"Purpose\u0000To assess efficacy, safety, and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015%/timolol 0.5% (PF tafluprost/timolol FC) in treatments-naïve patients with primary open-angle glaucoma (POAG).\u0000\u0000\u0000Methods\u0000This was a retrospective, real-world clinical practice setting study that included 107 eyes of 107 subjects with POAG who had never been treated for glaucoma. All subjects were received PF tafluprost/timolol FC once daily. Intraocular pressure (IOP) levels were documented for each eye at the untreated baseline and up to six months after the initiation of medical treatment. All adverse events, including ocular and systemic adverse reactions, were recorded. Additionally, the reasons for medication discontinuations were thoroughly documented.\u0000\u0000\u0000Results\u0000A total of 32 POAG patients with high-baseline IOP (> 21 mmHg) and 75 with normal-baseline IOP were included in the study. The subjects' baseline mean age was 62.4 ± 8.7 (range: 26 - 85 years); among them, 42 were women (39.3%). Mean IOP at baseline for all patients was 18.6 ± 4.3 mmHg. The mean IOP at six months was 12.6 ± 4.7 mmHg, representing a significant decrease compared to the baseline (-32%; P< 0.001). In POAG patients with high-baseline IOP, mean IOP was significantly lowered from 28.0 ± 5.7 mmHg at baseline to 18.0 ± 5.5 mmHg (-35%; P< 0.001); in patients with normal-baseline IOP, from 14.6 ± 3.4 mmHg to 10.3 ± 4.1 mmHg (-29%; P< 0.001). PF tafluprost/timolol FC was well tolerated and safe. After 6 months, 97.2% of all patients remained on therapy.\u0000\u0000\u0000Conclusions\u0000In this real-world observational study, once-daily treatment with PF tafluprost/timolol FC demonstrated clinically relevant and statistically significant efficacy, as well as safety and good tolerability, in treatment-naive patients diagnosed with POAG.","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":"15 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140652024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chanjoon Park, Da Ran Kim, Y. Yoon, Soonwon Yang, Woong-Joo Whang, Y. Byun, H. Hwang, K. Na, Hyun Soo Lee, So Hyang Chung, Eun Chul Kim, Y. Cho, Hyun Seung Kim, H. Hwang
Purpose In the present study, we introduce human lacrimal gland imaging using an ultrasound biomicroscopy (UBM) with a soft cover and show their findings. Methods The representative UBM findings of palpebral lobes in seven subjects (4 with non-Sjögren dry eye syndrome, 1 with Sjögren syndrome, and 2 healthy subjects) were described in this study. To prolapse the palpebral lobe, the examiner pulled the temporal part of the upper eyelid in the superotemporal direction and directed the subject to look in the inferonasal direction. We scanned the palpebral lobes longitudinally and transversely using UBM. We used an Aviso UBM (Quantel Medical, Clermont-Ferrand, France) with a 50 MHz linear probe and ClearScan. Results In UBM of two healthy subjects, the echogenicity of the lacrimal gland was lower than that of the sclera and homogeneous. But, the parenchyma of a patient with Sjögren dry eye syndrome was quite inhomogeneous compared to the healthy subjects. In two patients with dry eye syndrome, we were able to observe some lobules in the parenchyma. We could find excretory ducts running parallel at the surface of the longitudinal section in some subjects. In the longitudinal UBM scan of a subject, we observed a tubular structure at a depth of 1500 µm that was considered a blood vessel. It ran from the superonasal to the inferotemporal direction. In a subject, we observed a large cyst beneath the conjunctiva. Conclusions Lacrimal gland imaging using UBM has both advantages of OCT and sonography, and could be useful for evaluating dry eye syndrome.
{"title":"In Vivo Human Lacrimal Gland Imaging Using an Ultrasound Biomicroscopy.","authors":"Chanjoon Park, Da Ran Kim, Y. Yoon, Soonwon Yang, Woong-Joo Whang, Y. Byun, H. Hwang, K. Na, Hyun Soo Lee, So Hyang Chung, Eun Chul Kim, Y. Cho, Hyun Seung Kim, H. Hwang","doi":"10.3341/kjo.2023.0134","DOIUrl":"https://doi.org/10.3341/kjo.2023.0134","url":null,"abstract":"Purpose\u0000In the present study, we introduce human lacrimal gland imaging using an ultrasound biomicroscopy (UBM) with a soft cover and show their findings.\u0000\u0000\u0000Methods\u0000The representative UBM findings of palpebral lobes in seven subjects (4 with non-Sjögren dry eye syndrome, 1 with Sjögren syndrome, and 2 healthy subjects) were described in this study. To prolapse the palpebral lobe, the examiner pulled the temporal part of the upper eyelid in the superotemporal direction and directed the subject to look in the inferonasal direction. We scanned the palpebral lobes longitudinally and transversely using UBM. We used an Aviso UBM (Quantel Medical, Clermont-Ferrand, France) with a 50 MHz linear probe and ClearScan.\u0000\u0000\u0000Results\u0000In UBM of two healthy subjects, the echogenicity of the lacrimal gland was lower than that of the sclera and homogeneous. But, the parenchyma of a patient with Sjögren dry eye syndrome was quite inhomogeneous compared to the healthy subjects. In two patients with dry eye syndrome, we were able to observe some lobules in the parenchyma. We could find excretory ducts running parallel at the surface of the longitudinal section in some subjects. In the longitudinal UBM scan of a subject, we observed a tubular structure at a depth of 1500 µm that was considered a blood vessel. It ran from the superonasal to the inferotemporal direction. In a subject, we observed a large cyst beneath the conjunctiva.\u0000\u0000\u0000Conclusions\u0000Lacrimal gland imaging using UBM has both advantages of OCT and sonography, and could be useful for evaluating dry eye syndrome.","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140652866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eunhui Jo, Bokyung Kim, Tae-Im Kim, Mee Kum Kim, Chul Young Choi
Purpose To investigate the clinical outcomes of new hydrophobic trifocal intraocular lens (IOL) with hydroxyethyl methacrylate (HEMA) in the Korean population. Methods This prospective, multicenter, and observational study evaluated the clinical outcomes of eighty eyes of 40 patients with age-related cataract underwent cataract surgery using CNWT (Clareon PanOptix). Assessment included monocular and binocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA at 60cm), near visual acuity (UNVA at 40cm and 33cm), uncorrected defocus curves, questionnaires evaluating photic phenomena, spectacle independence and spectacle free satisfaction. Results At 3-month postoperatively, mean uncorrected binocular visual acuities were 0.04, 0.04, 0.03 logMAR at far, intermediate, and near distances respectively. All patients achieved uncorrected binocular VAs of 0.2 logMAR or better. Monocular and binocular defocus curve indicated a mean VA of 0.2 logMAR or better at the defocus range of +1.0 D to - 3.0D (100 cm to 33 cm) and +1.0 D to - 3.5 D (100 cm to 28 cm). High spectacle independence was observed at all distances, with 37.5% patients reporting photic phenomena. Conclusions The Clareon PanOptix IOL has shown positive clinical outcomes, providing a viable option for cataract surgery. These lenses effectively address patients' visual needs, especially in intermediate and near distance tasks, reducing dependence on glasses.
{"title":"Clinical Outcomes of A New Hydrophobic Trifocal Intraocular Lens with Hydroxyethyl Methacrylate in Cataract Surgery: A Prospective Multicenter Study.","authors":"Eunhui Jo, Bokyung Kim, Tae-Im Kim, Mee Kum Kim, Chul Young Choi","doi":"10.3341/kjo.2023.0140","DOIUrl":"https://doi.org/10.3341/kjo.2023.0140","url":null,"abstract":"Purpose\u0000To investigate the clinical outcomes of new hydrophobic trifocal intraocular lens (IOL) with hydroxyethyl methacrylate (HEMA) in the Korean population.\u0000\u0000\u0000Methods\u0000This prospective, multicenter, and observational study evaluated the clinical outcomes of eighty eyes of 40 patients with age-related cataract underwent cataract surgery using CNWT (Clareon PanOptix). Assessment included monocular and binocular uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity (UIVA at 60cm), near visual acuity (UNVA at 40cm and 33cm), uncorrected defocus curves, questionnaires evaluating photic phenomena, spectacle independence and spectacle free satisfaction.\u0000\u0000\u0000Results\u0000At 3-month postoperatively, mean uncorrected binocular visual acuities were 0.04, 0.04, 0.03 logMAR at far, intermediate, and near distances respectively. All patients achieved uncorrected binocular VAs of 0.2 logMAR or better. Monocular and binocular defocus curve indicated a mean VA of 0.2 logMAR or better at the defocus range of +1.0 D to - 3.0D (100 cm to 33 cm) and +1.0 D to - 3.5 D (100 cm to 28 cm). High spectacle independence was observed at all distances, with 37.5% patients reporting photic phenomena.\u0000\u0000\u0000Conclusions\u0000The Clareon PanOptix IOL has shown positive clinical outcomes, providing a viable option for cataract surgery. These lenses effectively address patients' visual needs, especially in intermediate and near distance tasks, reducing dependence on glasses.","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":"92 16","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140676791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eoi Jong Seo, Moon Sun Jung, Kibum Lee, Kyung Tae Kim, Mi Young Choi
Background To evaluate the ocular adverse event (OAE) and the incidence rate that can occur after coronavirus disease-2019 (COVID-19) vaccination. Methods Patients who visited with an ophthalmologic diagnosis within a month of COVID-19 vaccination were retrospectively analyzed. OAEs were categorized as ischemia and inflammation by their presumed pathogenesis, and were compared by types of vaccine: messenger ribonucleic acid (mRNA) and viral vector vaccine. The crude incidence rate was calculated using data from the Korea Disease Control and Prevention Agency. Results Twenty-four patients with OAEs after COVID-19 vaccination were reviewed: 10 patients after mRNA and 14 after viral vector vaccine. Retinal vein occlusion (9 patients) and paralytic strabismus (4 patients) were the leading diagnoses. Ischemic OAE was likely to occur after viral vector vaccines, while inflammatory OAE was closely related to mRNA vaccine (p=0.017). The overall incidence rate of OAE was 5.8 cases per million doses: 11.5 per million doses in viral vector vaccine and 3.4 per million doses in mRNA vaccine. Conclusion OAEs can be observed shortly after the COVID-19 vaccination, and their category was different based on the types of vaccine. The information and incidence of OAE based on the type of vaccine can help monitor patients who were administered the COVID-19 vaccine.
{"title":"Ischemic and Inflammatory Ocular Adverse Events Following Different Types of Vaccination for COVID-19, and Their Incidence Analysis.","authors":"Eoi Jong Seo, Moon Sun Jung, Kibum Lee, Kyung Tae Kim, Mi Young Choi","doi":"10.3341/kjo.2023.0090","DOIUrl":"https://doi.org/10.3341/kjo.2023.0090","url":null,"abstract":"Background\u0000To evaluate the ocular adverse event (OAE) and the incidence rate that can occur after coronavirus disease-2019 (COVID-19) vaccination.\u0000\u0000\u0000Methods\u0000Patients who visited with an ophthalmologic diagnosis within a month of COVID-19 vaccination were retrospectively analyzed. OAEs were categorized as ischemia and inflammation by their presumed pathogenesis, and were compared by types of vaccine: messenger ribonucleic acid (mRNA) and viral vector vaccine. The crude incidence rate was calculated using data from the Korea Disease Control and Prevention Agency.\u0000\u0000\u0000Results\u0000Twenty-four patients with OAEs after COVID-19 vaccination were reviewed: 10 patients after mRNA and 14 after viral vector vaccine. Retinal vein occlusion (9 patients) and paralytic strabismus (4 patients) were the leading diagnoses. Ischemic OAE was likely to occur after viral vector vaccines, while inflammatory OAE was closely related to mRNA vaccine (p=0.017). The overall incidence rate of OAE was 5.8 cases per million doses: 11.5 per million doses in viral vector vaccine and 3.4 per million doses in mRNA vaccine.\u0000\u0000\u0000Conclusion\u0000OAEs can be observed shortly after the COVID-19 vaccination, and their category was different based on the types of vaccine. The information and incidence of OAE based on the type of vaccine can help monitor patients who were administered the COVID-19 vaccine.","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":"47 S224","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sungchul Choi, Jae Won Jun, Younghyun Kim, Junyeong Ahn, Sanghyuk Yim, Kyubae Lee, Chan Yun Kim, Wungrak Choi
{"title":"Capsular Tension Ring for Hypotony Maculopathy Secondary to Traumatic Cyclodialysis Cleft: A Case Report.","authors":"Sungchul Choi, Jae Won Jun, Younghyun Kim, Junyeong Ahn, Sanghyuk Yim, Kyubae Lee, Chan Yun Kim, Wungrak Choi","doi":"10.3341/kjo.2023.0122","DOIUrl":"https://doi.org/10.3341/kjo.2023.0122","url":null,"abstract":"","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":"89 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140710971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose To evaluate the efficacy of intravitreal brolucizumab in polyp regression of treatment-naïve polypoidal choroidal vasculopathy (PCV) patients and its effect on one-year treatment outcome. Methods Medical records of 31 treatment-naïve PCV patients, who received three monthly intravitreal brolucizumab injections followed by as-needed injections for at least a year, were retrospectively reviewed. Visual and anatomical outcomes were evaluated at 3-month, 6-month, and 12-month. Complete polyp regression rate and percentage change of vascular lesion and polyp area were evaluated after three monthly injections of brolucizumab. The effect of complete polyp regression and the impact of vascular lesion and polyp reduction rate on one-year treatment outcome were also evaluated. Additionally, the incidence of brolucizumab-related intraocular inflammation (IOI) and its clinical course were examined. Results In terms of visual outcome, best-corrected visual acuity(BCVA) significantly improved after 12 month follow-up (p<0.001). In terms of anatomical outcome, central macular thickness(CMT) and central choroidal thickness(CCT) significantly decreased after 12 month follow-up (p<0.001). Complete polyp regression was observed in 74.2% (23/31) after three monthly injections. Group with complete polyp regression had a higher rate of achieving dry macula at 3-month(p=0.026) and fewer number of injections(p<0.001) compared to the group without complete polyp regression. Higher polyp reduction rate was significantly associated with higher CMT change from baseline at 3-month (p=0.048) while higher vascular lesion reduction rate was significantly associated with higher CMT change from baseline at 12-month(p=0.031) and fewer number of injections(p=0.012). Brolucizumab related IOI occurred in one eye (1/31, 3.2%). Conclusion Intravitreal brolucizumab injection effectively improved visual and anatomical outcomes and achieved significant polyp regression in treatment-naïve PCV patients. Complete polyp regression and the reduction rate of vascular lesion size and polyp size after loading injection significantly influence the treatment outcome of PCV patients. However, careful monitoring and preoperative warning is warranted due to occurrence of brolucizumab-related IOI.
{"title":"Efficacy of Brolucizumab in Polyp Regression of Treatment-Naïve Polypoidal Choroidal Vasculopathy and Its Effect on One-Year Treatment Outcome.","authors":"Seung Hun Lee, Hyo Song Park, Jung Woo Han","doi":"10.3341/kjo.2023.0145","DOIUrl":"https://doi.org/10.3341/kjo.2023.0145","url":null,"abstract":"Purpose\u0000To evaluate the efficacy of intravitreal brolucizumab in polyp regression of treatment-naïve polypoidal choroidal vasculopathy (PCV) patients and its effect on one-year treatment outcome.\u0000\u0000\u0000Methods\u0000Medical records of 31 treatment-naïve PCV patients, who received three monthly intravitreal brolucizumab injections followed by as-needed injections for at least a year, were retrospectively reviewed. Visual and anatomical outcomes were evaluated at 3-month, 6-month, and 12-month. Complete polyp regression rate and percentage change of vascular lesion and polyp area were evaluated after three monthly injections of brolucizumab. The effect of complete polyp regression and the impact of vascular lesion and polyp reduction rate on one-year treatment outcome were also evaluated. Additionally, the incidence of brolucizumab-related intraocular inflammation (IOI) and its clinical course were examined.\u0000\u0000\u0000Results\u0000In terms of visual outcome, best-corrected visual acuity(BCVA) significantly improved after 12 month follow-up (p<0.001). In terms of anatomical outcome, central macular thickness(CMT) and central choroidal thickness(CCT) significantly decreased after 12 month follow-up (p<0.001). Complete polyp regression was observed in 74.2% (23/31) after three monthly injections. Group with complete polyp regression had a higher rate of achieving dry macula at 3-month(p=0.026) and fewer number of injections(p<0.001) compared to the group without complete polyp regression. Higher polyp reduction rate was significantly associated with higher CMT change from baseline at 3-month (p=0.048) while higher vascular lesion reduction rate was significantly associated with higher CMT change from baseline at 12-month(p=0.031) and fewer number of injections(p=0.012). Brolucizumab related IOI occurred in one eye (1/31, 3.2%).\u0000\u0000\u0000Conclusion\u0000Intravitreal brolucizumab injection effectively improved visual and anatomical outcomes and achieved significant polyp regression in treatment-naïve PCV patients. Complete polyp regression and the reduction rate of vascular lesion size and polyp size after loading injection significantly influence the treatment outcome of PCV patients. However, careful monitoring and preoperative warning is warranted due to occurrence of brolucizumab-related IOI.","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":"46 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140731702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hee Kyung Yang, Shin Hae Park, Haeng-Jin Lee, Sook-Young Kim, H. J. Gye, So Young Kim, Sun Young Shin, Key Hwan Lim
Purpose To determine subjective symptoms and medical history of patients with intermittent exotropia in a large study population. Methods The Korean Intermittent Exotropia Multicenter Study (KIEMS) is a nationwide, observational, cross-sectional, multicenter study conducted by the Korean Association for Pediatric Ophthalmology and Strabismus (KAPOS) including 5385 patients with intermittent exotropia. Subjective symptoms and medical history of patients with intermittent exotropia were extracted by a comprehensive survey based on a self-administered questionnaire according to the study protocol of the KIEMS. Results The mean age of symptom onset was 5.5 years of age. The most common symptom reported in patients with intermittent exotropia was photophobia (52.1%), followed by diplopia at near (7.3%) and distance fixation (6.2%). Preterm birth was found in 8.8%, and 4.1% had perinatal complications. A family history of strabismus was present in 14.9%, and 5.5% of patients had a family member who underwent strabismus surgery. Conclusions The KIEMS is one of the largest clinical studies on intermittent exotropia. Intermittent exotropia frequently caused photophobia and diplopia, and patients with a family history was not uncommon.
{"title":"Self-reported Findings of the Korean Intermittent Exotropia Multicenter Study Questionnaire.","authors":"Hee Kyung Yang, Shin Hae Park, Haeng-Jin Lee, Sook-Young Kim, H. J. Gye, So Young Kim, Sun Young Shin, Key Hwan Lim","doi":"10.3341/kjo.2023.0129","DOIUrl":"https://doi.org/10.3341/kjo.2023.0129","url":null,"abstract":"Purpose\u0000To determine subjective symptoms and medical history of patients with intermittent exotropia in a large study population.\u0000\u0000\u0000Methods\u0000The Korean Intermittent Exotropia Multicenter Study (KIEMS) is a nationwide, observational, cross-sectional, multicenter study conducted by the Korean Association for Pediatric Ophthalmology and Strabismus (KAPOS) including 5385 patients with intermittent exotropia. Subjective symptoms and medical history of patients with intermittent exotropia were extracted by a comprehensive survey based on a self-administered questionnaire according to the study protocol of the KIEMS.\u0000\u0000\u0000Results\u0000The mean age of symptom onset was 5.5 years of age. The most common symptom reported in patients with intermittent exotropia was photophobia (52.1%), followed by diplopia at near (7.3%) and distance fixation (6.2%). Preterm birth was found in 8.8%, and 4.1% had perinatal complications. A family history of strabismus was present in 14.9%, and 5.5% of patients had a family member who underwent strabismus surgery.\u0000\u0000\u0000Conclusions\u0000The KIEMS is one of the largest clinical studies on intermittent exotropia. Intermittent exotropia frequently caused photophobia and diplopia, and patients with a family history was not uncommon.","PeriodicalId":101356,"journal":{"name":"Korean journal of ophthalmology : KJO","volume":"21 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140728836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号